This tactic turned out to be useful when fusing pharmacological scaffolds from a MAO-B inhibitor and an AChE inhibitor together to afford multi-target-directed lead compounds as potential therapeutics against AD [134,135]. Here, MAOB is linked to Alzheimer disease.